Recurrent Dermatophytosis in 10marks format for third year derma post graduate
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
I now have comprehensive information from authoritative textbooks to construct a thorough 10-mark answer. Let me compile this into a well-structured format suitable for a third-year dermatology postgraduate exam.
Recurrent Dermatophytosis
Definition
Recurrent dermatophytosis refers to repeated episodes of dermatophyte infection in the same or different anatomical sites following apparent clinical cure, or persistent/chronic infection that fails to resolve despite adequate antifungal therapy. It is a major clinical challenge in dermatological practice and represents an interplay of host, pathogen, and environmental factors.
Causative Organisms
Dermatophytes belong to three genera: Trichophyton, Microsporum, and Epidermophyton. These organisms invade only keratinized structures (stratum corneum, hair, nails).
The organisms most commonly implicated in recurrent/chronic disease include:
| Species | Relevance to Recurrence |
|---|---|
| T. rubrum | Most common; harbored in hair follicles, mannans suppress epidermal proliferation and immune response; can survive as inert conidia |
| T. tonsurans | Endothrix infection; reservoir in hair follicles |
| T. concentricum | Causes tinea imbricata — typically chronic and relapsing |
| T. indotineae (formerly T. mentagrophytes ITS genotype VIII) | Terbinafine-resistant strains; causes large annular widespread lesions; epidemic in India with global spread |
| E. floccosum | Groin and feet; recurrent tinea cruris |
— Dermatology 2-Volume Set 5e (Elsevier), and Fitzpatrick's Dermatology Vol. 1 & 2
Pathogenesis of Recurrence
1. Pathogen-mediated Immune Evasion (Key Mechanism)
T. rubrum is the prototype organism for chronicity:
- Mannans in the fungal cell wall suppress epidermal proliferation (reducing sloughing before invasion) and inhibit lymphocyte proliferation and keratinocyte immune responses.
- After an initial brief inflammatory response, T. rubrum downregulates TLR2 and TLR6 expression on keratinocytes, decreasing secretion of human beta-defensin-1 and -2.
- Viable intact conidia inhibit TLR2/TLR6 and reduce antimicrobial peptide output.
- When phagocytized, T. rubrum conidia manipulate macrophages: they increase TNF-α and IL-10 without increasing IL-12 or nitric oxide, downregulate co-stimulatory molecules, and inhibit phagocytosis — conidia then continue to grow inside the macrophage until it ruptures.
- Conidia thus survive as inert forms until environmental conditions favour germination, leading to recurrent infection.
— Fitzpatrick's Dermatology Vol. 1 & 2, p. 2958
2. Defective Host Immunity
- Defective Th1 cell-mediated immunity: The delayed-type hypersensitivity response correlates with clinical resolution; its failure leads to chronic/recurrent disease.
- Elevated Th2 response (elevated fungal antigen antibody titers) is associated with widespread infection, not protection.
- Th17 pathway: IL-17 responses restrict dermatophyte infections. Genetic defects in IL-17 signaling increase susceptibility.
- Dectin-1 deficiency and CARD9 mutations: Dectin-1 (C-type lectin receptor) binding β-1,3-glucan activates the SYK-CARD9-IL-23-Th17 axis. Loss-of-function mutations in CARD9 cause chronic mucocutaneous dermatophytosis and susceptibility to invasive dissemination.
- Other genetic mutations increasing susceptibility: IL-17 receptor, STAT1, STAT3, DOCK8, Tyk2, AIRE, MST1/STK4.
- Blood group type A confers increased susceptibility to chronic disease.
— Fitzpatrick's Dermatology Vol. 1 & 2, pp. 2162–2178
3. Host Risk Factors
| Category | Specific Factors |
|---|---|
| Immunosuppression | HIV infection, solid organ transplant recipients, systemic corticosteroids, calcineurin inhibitors |
| Immune deficiencies | Chronic mucocutaneous candidiasis, common variable immunodeficiency, CARD9 deficiency |
| Metabolic | Diabetes mellitus (especially poorly controlled) |
| Skin barrier defects | Ichthyosis, hyperhidrosis, maceration |
| Anatomical | Onychomycosis (nail reservoir), tinea pedis feeding tinea cruris/corporis |
| Topical corticosteroid misuse | Creates "tinea incognita" — altered morphology, reduced inflammation, deeper follicular spread |
| Genetic | Autosomal dominant asymptomatic carriage of T. rubrum; polymorphisms in TLRs, Dectin-1, CARD9 |
— Dermatology 2-Volume Set 5e; Andrews' Diseases of the Skin
4. Environmental and Behavioural Factors
- Occlusive, non-breathable footwear; hyperhidrosis; athletics/swimming (tinea pedis)
- Contaminated fomites: hairbrushes, barber instruments, wet floors, locker rooms
- Reinfection from untreated household contacts or pets
- Old shoes harbouring large numbers of infectious organisms
- Hot, humid climates
5. Antifungal Resistance
A critical emerging cause of recurrent/treatment-refractory dermatophytosis:
- Squalene epoxidase (SQLE) mutations → terbinafine resistance in T. rubrum and T. indotineae
- T. indotineae has caused an epidemic of resistant dermatophytosis in India with subsequent global spread
- Overuse of topical corticosteroid-antifungal combination products promotes resistance and inadequate treatment
- CYP51 mutations can confer azole resistance
— Dermatology 2-Volume Set 5e, p. 2346
Clinical Features of Recurrent/Chronic Disease
- Tinea pedis: Most commonly recurs; characterized by chronic erythema, scaling, hyperkeratosis of soles; may persist for years; onychomycosis serves as a constant reservoir for reinfection.
- Tinea unguium/Onychomycosis: Opacified, thickened, crumbling nails with subungual debris; recurrence common after treatment, especially in toenails and severe involvement.
- Tinea corporis: Widespread, coalescing annular plaques; concentric rings with T. rubrum; when pretreated with corticosteroids, may lose the characteristic ring appearance (tinea incognita).
- Tinea cruris: Recurrence often due to concomitant tinea pedis or onychomycosis serving as source; both sites must be treated simultaneously.
- Tinea capitis: Chronic infection especially in immunocompromised adults; T. tonsurans causes non-inflammatory diffuse scaling with alopecia.
- Tinea imbricata: Chronic, lifelong, concentric scaling plaques caused by T. concentricum in endemic regions (South Pacific, South America).
- Majocchi granuloma / tinea profunda: Deep follicular infection, nodular perifolliculitis; occurs with immunosuppression or follicular trauma; granulomatous/verrucous appearance.
- Invasive/disseminated dermatophytosis: Rare; ulcerating or draining dermal nodules; occurs in CARD9 deficiency or iatrogenic immunosuppression.
Investigations
| Investigation | Method | Significance |
|---|---|---|
| KOH preparation (10–20%) | Scale from active advancing border; septate branching hyphae | Quick bedside confirmation; false-negative in up to 15% |
| Fungal culture (Sabouraud's medium) | Microscopy of microconidia/macroconidia; colony morphology | Species identification; antifungal susceptibility testing |
| Dermatophyte Test Medium (DTM) | Yellow → red colour change in 5–14 days | Rapid screening |
| Histopathology (PAS, GMS stains) | Skin or nail biopsy | Demonstrates hyphae in stratum corneum; useful when culture negative |
| Wood's lamp | Green fluorescence | Limited: only M. canis and a few others fluoresce |
| Antifungal susceptibility testing (MIC) | Broth microdilution (EUCAST/CLSI) | Mandatory in recurrent/recalcitrant cases to detect resistance |
| Immune workup | CD4 count, immunoglobulins, Dectin-1/CARD9 mutation screen | In young patients with severe/recurrent disease |
For recurrent disease, culture with susceptibility testing is mandatory to exclude antifungal resistance, particularly to terbinafine.
Management
Principles
- Confirm diagnosis mycologically before systemic therapy.
- Identify and treat the reservoir (onychomycosis, tinea pedis, scalp) and contacts.
- Address underlying predisposing factors (diabetes, immunosuppression, corticosteroid misuse).
- Choose antifungal based on susceptibility testing in recurrent disease.
- Treat all involved sites simultaneously.
Topical Antifungals
Effective for limited tinea corporis, cruris, and pedis:
- Allylamines: Terbinafine 1%, naftifine, butenafine (inhibit squalene epoxidase)
- Imidazoles: Clotrimazole, miconazole, econazole, ketoconazole 2%
- Ciclopirox olamine 0.77–1% (broader spectrum; useful in mixed infections)
- Apply twice daily; continue 1 week beyond clinical resolution
- Apply several hand-widths beyond visible lesion borders
Systemic Antifungals
Indicated for: hair-bearing areas, onychomycosis, extensive/recalcitrant disease, immunosuppression, folliculitis, terbinafine-sensitive strains:
| Drug | Dose | Indication |
|---|---|---|
| Terbinafine | 250 mg/day × 2–4 weeks (skin); 6 weeks fingernails; 12–16 weeks toenails | First-line for most tinea; fungicidal; fewer drug interactions |
| Itraconazole | 200 mg/day × 7 days or pulse therapy 200 mg BD × 1 week/month × 2–3 pulses (nails) | Tinea corporis, onychomycosis; avoid in heart failure; multiple CYP450 interactions |
| Fluconazole | 150 mg weekly × 2–4 weeks | Tinea pedis/corporis; off-label; useful in children |
| Griseofulvin | 500 mg–1 g/day with fatty food; 6–8 weeks (skin), 4–6 months (nails) | Standard for tinea capitis in children; long course required |
| Posaconazole/Voriconazole | Per susceptibility | Terbinafine-resistant T. indotineae; invasive dermatophytosis |
Caution: Systemic ketoconazole is no longer recommended for superficial fungal infections due to hepatotoxicity.
Recurrent/Resistant Cases
- Send for culture + MIC testing before escalating therapy
- For terbinafine-resistant T. indotineae: use itraconazole (susceptibility usually retained), posaconazole, or voriconazole
- Invasive dermatophytosis: surgical excision (if localized) + systemic terbinafine, itraconazole, or posaconazole
- Avoid combination topical corticosteroid-antifungal products — unacceptable failure rate; promotes steroid side effects (striae) and drug resistance
Prevention of Recurrence
- Treat all sites simultaneously (tinea pedis + cruris + nails)
- Breathable footwear and moisture-wicking socks; absorbent/antifungal powders
- Frequent nail clipping; discard or treat old contaminated footwear
- Maintenance topical antifungal applied weekly to previously affected sites
- Screen and treat household contacts; treat infected pets
- Antifungal shampoo 1–2×/week for tinea capitis contacts
- Optimize glycaemic control in diabetics; review immunosuppressive regimens where possible
— Harrison's Principles of Internal Medicine 22E; Dermatology 2-Volume Set 5e; Andrews' Diseases of the Skin
Summary of Key Points for Exam
- T. rubrum is the most common cause of recurrent dermatophytosis and evades immunity via mannan-mediated immune suppression and TLR downregulation.
- Defective Th1/Th17 immunity (CARD9 mutations, STAT1/3 defects) is the major immunogenetic predisposition.
- Onychomycosis is the most important internal reservoir driving recurrence.
- T. indotineae — terbinafine-resistant strains — represents an emerging cause of refractory dermatophytosis, especially from the Indian subcontinent.
- Culture + susceptibility testing is essential in recurrent disease.
- Combined corticosteroid-antifungal products must be avoided — they cause treatment failure and drug resistance.
- Management requires simultaneous treatment of all reservoirs + addressing host risk factors + antifungal stewardship.
This is a shared conversation. Sign in to Orris to start your own chat.